Usefulness of procalcitonin in inflammatory bowel disease: A systematic review and meta-analysis

Donna Ann Cheung, Leonardo Tamariz, Zsuzsanna Nemeth, Amber Hamid Langshaw

Research output: Contribution to journalReview articlepeer-review

1 Scopus citations

Abstract

Background: Mixed results are reported for procalcitonin (PCT) as biomarkers of infection and disease activity in inflammatory bowel disease (IBD). Method: We systematically evaluated and performed a meta-analysis on the usefulness of PCT in assessing infection and disease activity in IBD. Results: The pooled standardized mean difference of PCT for those with infection compared with those without was 1.59 (95% CI, 0.72-2.46, P < 0.01) and those with active disease compared with those without was 1.22 (95% CI, 0.66-1.78, P < 0.01), respectively. Conclusion: PCT may potentially be useful in differentiating an infectious process from IBD and active from inactive IBD.

Original languageEnglish (US)
JournalCrohn's and Colitis 360
Volume1
Issue number3
DOIs
StatePublished - Oct 1 2019

Keywords

  • Activity
  • Biomarker
  • Crohn
  • Infection
  • Ulcerative colitis

ASJC Scopus subject areas

  • Gastroenterology

Fingerprint

Dive into the research topics of 'Usefulness of procalcitonin in inflammatory bowel disease: A systematic review and meta-analysis'. Together they form a unique fingerprint.

Cite this